• Coumestrol Induces Ferroptosis in RA Synoviocytes via PMAIP1

  2026-06-24

  The reference study establishes that Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes by stabilizing mitochondrial PMAIP1 through inhibition of the TRIM3-mediated ubiquitin-proteasome pathway. These findings highlight a novel cellular mechanism for suppressing synovial proliferation and inflammation, suggesting new avenues for selective estrogen receptor modulator (SERM) studies targeting autoimmune disease.

• Nullscript: A Precise Histone Deacetylase Inhibitor for Card

  2026-06-23

  Nullscript offers researchers a uniquely selective approach to HDAC inhibition, proving effective in reducing myocardial infarct size without transcriptional facilitation. Its distinct inactivity at the p6SBE-luc reporter and robust in vivo profile set it apart for targeted cardiac, neurodegenerative, and cancer research.

• EPZ-6438: EZH2 Inhibitor Workflows for Epigenetic Cancer Mod

  2026-06-23

  EPZ-6438 empowers researchers to dissect the polycomb repressive complex 2 pathway with precision, enabling robust antiproliferative assays and gene expression analyses in cancer models. This guide translates recent breakthroughs into actionable protocols, troubleshooting strategies, and workflow optimizations for advanced epigenetic research.

• Bafilomycin A1: V-ATPase Inhibitor for Lysosomal Function Re

  2026-06-22

  Bafilomycin A1 stands out as a gold-standard V-ATPase inhibitor, empowering precise dissection of lysosomal function, intracellular pH regulation, and cellular trafficking. This guide delivers stepwise protocols, advanced troubleshooting, and actionable insights from the latest experimental studies, ensuring researchers achieve robust, reproducible results.

• Olaparib (AZD2281): Mechanisms, Strategy, and Next-Gen Oncol

  2026-06-22

  This thought-leadership article synthesizes mechanistic insight and strategic guidance for translational researchers advancing DNA damage response research. Bridging the latest discoveries in metabolic regulation of homologous recombination, it situates Olaparib (AZD2281, Ku-0059436) as a cornerstone of BRCA-associated cancer therapy, tumor radiosensitization, and innovative assay development. Grounded in recent literature and referencing both APExBIO product expertise and related content assets, this discussion uniquely integrates experimental, clinical, and strategic outlooks for the evolving landscape of precision oncology.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-06-21

  CUDC-907 offers researchers a potent tool for in vitro studies requiring simultaneous inhibition of PI3K and HDAC pathways, supporting the investigation of cell cycle arrest, apoptosis, and signaling in cancer cell models. Its application is limited to research workflows and is not suited for diagnostic or therapeutic purposes.

• Stattic: STAT3 Inhibitor Workflows for Cancer and Psoriasis

  2026-06-20

  Stattic, a potent STAT3 inhibitor from APExBIO, enables precise dissection of STAT3-driven pathways in both cancer and inflammatory skin disease models. This guide distills the latest experimental advances, including practical protocol enhancements and troubleshooting tips, to maximize the translational impact of Stattic in apoptosis induction, radiosensitization, and beyond.

• Iptacopan (LNP023): Selective Alternative Pathway Inhibition

  2026-06-19

  Iptacopan (LNP023) is a highly selective, reversible oral inhibitor of complement factor B, enabling precise blockade of the alternative complement pathway. It demonstrates potent nanomolar activity in enzymatic and cell-based assays and is validated in animal models and early-phase clinical studies for PNH and C3G. The product, offered by APExBIO, establishes a benchmark for complement activation research and translational applications.

• Q-VD-OPh: Pan-Caspase Inhibitor Workflows in Apoptosis Resea

  2026-06-19

  Q-VD-OPh stands out as a potent, selective pan-caspase inhibitor, enabling precise dissection of apoptosis pathways and enhancing experimental reproducibility across in vitro and in vivo settings. Its unique cell and brain permeability, broad caspase inhibition, and proven application in disease models make it indispensable for both mechanistic research and translational workflows.

• Br-DAPI: High-Sensitivity DAPI Fluorescent Dye for DNA Stain

  2026-06-18

  Br-DAPI is a next-generation DAPI fluorescent dye that delivers robust, selective DNA staining for both live and fixed cells. This product amplifies fluorescence up to 20-fold upon A/T-rich DNA binding, enabling highly sensitive DNA quantification and visualization in cell biology workflows.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis & Signaling

  2026-06-18

  JNK-IN-7 is a selective JNK inhibitor with nanomolar potency that enables precise dissection of MAPK signaling and apoptosis pathways. Its covalent inhibition of JNK isoforms supports advanced research in inflammation and innate immune modulation.

• DMG-PEG2000-NH2: Redefining Lipid-Based Drug Delivery Platfo

  2026-06-17

  This article explores the mechanistic strengths and translational strategies unlocked by DMG-PEG2000-NH2, an advanced NH2-PEG derivative. We synthesize current evidence and competitive insights for researchers optimizing lipid nanoparticle (LNP) and liposomal platforms, emphasizing practical protocol parameters and the evolving therapeutic landscape.

• RNA Pol II Inhibition Triggers Apoptosis via Pol IIA Loss, N

  2026-06-17

  Harper et al. (2025) uncover that inhibiting RNA Pol II activates a regulated apoptotic pathway independent of transcriptional shutdown, triggered specifically by depletion of hypophosphorylated RNA Pol IIA. This mechanistic insight reframes how cell death is initiated during transcriptional inhibition and has implications for cancer therapy development.

• SHC-1 Inhibition Enhances CFTR Surface Abundance in Epitheli

  2026-06-16

  This study reveals how SHC-1, via the MAPK pathway, regulates the internalization and plasma membrane abundance of the CFTR chloride channel in various epithelial cell models. By comparing pharmacological SHC-1 inhibitors, the research clarifies cell-type-specific responses, informing assay design and mechanistic understanding for cystic fibrosis and secretory diarrheal disease research.

• SmD2 Acetylation Regulates Splicing and PARP Sensitivity in

  2026-06-16

  This study uncovers how acetylation-dependent regulation of the spliceosome core component SmD2 influences alternative splicing and DNA damage response in hepatocellular carcinoma (HCC). By linking HDAC2-mediated deacetylation of SmD2 to splicing control and demonstrating that HDAC inhibition (via Romidepsin) synergizes with PARP inhibition, the paper identifies new combinatorial therapeutic strategies for HCC.

11328 records 1/756 page Next 12345 下5页 Last page